Stimulation of α7 nicotinic acetylcholine receptor by AR-R17779 suppresses atherosclerosis and aortic aneurysm formation in apolipoprotein E-deficient mice

Vascular Pharmacology

Volumn 61, Issue 2-3, 2014, Pages 49-55

  Hashimoto, Toru ^a   Ichiki, Toshihiro ^a   Watanabe, Aya ^a   Hurt Camejo, Eva ^b   Michaëlsson, Erik ^b   Ikeda, Jiro ^a   Inoue, Eriko ^a   Matsuura, Hirohide ^a   Tokunou, Tomotake ^a   Kitamoto, Shiro ^a   Sunagawa, Kenji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Angiotensin receptor; Atherosclerosis; Cholinergic anti inflammatory pathway; Inflammation; 7 Nicotinic acetylcholine receptor

Indexed keywords

ANGIOTENSIN II; APOLIPOPROTEIN E; BUNGAROTOXIN RECEPTOR; DRINKING WATER; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPID; MESSENGER RNA; NICOTINIC AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SPIRO[1 AZABICYCLO[2.2.2]OCTANE 3,2' THIAZOLIDINE] 2' ONE; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; AR-R 17779; BRIDGED COMPOUND; SPIRO COMPOUND;

ABDOMINAL AORTA ANEURYSM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE; CONTROLLED STUDY; GENE EXPRESSION; LIPID BLOOD LEVEL; LIPID DIET; MALE; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; SURVIVAL; TREATMENT RESPONSE; AGONISTS; ANIMAL; AORTIC ANEURYSM; BLOOD; DISEASE MODEL; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; METABOLISM; RAT; SPRAGUE DAWLEY RAT;

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANIMALS; ANTI-INFLAMMATORY AGENTS; AORTIC ANEURYSM; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD PRESSURE; BRIDGED COMPOUNDS; DISEASE MODELS, ANIMAL; LIPIDS; MALE; MICE; MICE, KNOCKOUT; RATS; RATS, SPRAGUE-DAWLEY; SPIRO COMPOUNDS;

EID: 84900843035     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2014.03.006     Document Type: Article

References (47)

1. O'Keefe J.H., Carter M.D., Lavie C.J. Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clin Proc 2009, 84:741-757.
2. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
3. Libby P., Ridker P.M., Hansson G.K. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009, 54:2129-2138.
4. Ohsuzu F. The roles of cytokines, inflammation and immunity in vascular diseases. J Atheroscler Thromb 2004, 11:313-321.
5. Tracey K.J. The inflammatory reflex. Nature 2002, 420:853-859.
6. Tracey K.J. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest 2007, 117:289-296.
7. Borovikova L.V., Ivanova S., Zhang M., Yang H., Botchkina G.I., Watkins L.R., et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000, 405:458-462.
8. Borovikova L.V., Ivanova S., Nardi D., Zhang M., Yang H., Ombrellino M., et al. Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation. Auton Neurosci 2000, 85:141-147.
9. Bernik T.R., Friedman S.G., Ochani M., DiRaimo R., Susarla S., Czura C.J., et al. Cholinergic antiinflammatory pathway inhibition of tumor necrosis factor during ischemia reperfusion. J Vasc Surg 2002, 36:1231-1236.
10. Mioni C., Bazzani C., Giuliani D., Altavilla D., Leone S., Ferrari A., et al. Activation of an efferent cholinergic pathway produces strong protection against myocardial ischemia/reperfusion injury in rats. Crit Care Med 2005, 33:2621-2628.
11. Altavilla D., Guarini S., Bitto A., Mioni C., Giuliani D., Bigiani A., et al. Activation of the cholinergic anti-inflammatory pathway reduces NF-kappab activation, blunts TNF-alpha production, and protects against splanchic artery occlusion shock. Shock 2006, 25:500-506.
12. Guarini S., Altavilla D., Cainazzo M.M., Giuliani D., Bigiani A., Marini H., et al. Efferent vagal fibre stimulation blunts nuclear factor-kappaB activation and protects against hypovolemic hemorrhagic shock. Circulation 2003, 107:1189-1194.
13. de Jonge W.J., van der Zanden E.P., The F.O., Bijlsma M.F., van Westerloo D.J., Bennink R.J., et al. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol 2005, 6:844-851.
14. Bernik T.R., Friedman S.G., Ochani M., DiRaimo R., Ulloa L., Yang H., et al. Pharmacological stimulation of the cholinergic antiinflammatory pathway. J Exp Med 2002, 195:781-788.
15. Luyer M.D., Greve J.W., Hadfoune M., Jacobs J.A., Dejong C.H., Buurman W.A. Nutritional stimulation of cholecystokinin receptors inhibits inflammation via the vagus nerve. J Exp Med 2005, 202:1023-1029.
16. van Westerloo D.J., Giebelen I.A., Florquin S., Daalhuisen J., Bruno M.J., de Vos A.F., et al. The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis. J Infect Dis 2005, 191:2138-2148.
17. Ghia J.E., Blennerhassett P., Kumar-Ondiveeran H., Verdu E.F., Collins S.M. The vagus nerve: a tonic inhibitory influence associated with inflammatory bowel disease in a murine model. Gastroenterology 2006, 131:1122-1130.
18. van Westerloo D.J., Giebelen I.A., Florquin S., Bruno M.J., Larosa G.J., Ulloa L., et al. The vagus nerve and nicotinic receptors modulate experimental pancreatitis severity in mice. Gastroenterology 2006, 130:1822-1830.
19. Wang H., Yu M., Ochani M., Amella C.A., Tanovic M., Susarla S., et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003, 421:384-388.
20. Wang H., Liao H., Ochani M., Justiniani M., Lin X., Yang L., et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004, 10:1216-1221.
21. Gavrila D., Li W.G., McCormick M.L., Thomas M., Daugherty A., Cassis L.A., et al. Vitamin E inhibits abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2005, 25:1671-1677.
22. Daugherty A., Manning M.W., Cassis L.A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000, 105:1605-1612.
23. Weiss D., Kools J.J., Taylor W.R. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 2001, 103:448-454.
24. Ni W., Kitamoto S., Ishibashi M., Usui M., Inoue S., Hiasa K., et al. Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol 2004, 24:534-539.
25. Manning M.W., Cassis L.A., Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2003, 23:483-488.
26. Johnsen S.H., Forsdahl S.H., Singh K., Jacobsen B.K. Atherosclerosis in abdominal aortic aneurysms: a causal event or a process running in parallel?. The Tromso study. Arterioscler Thromb Vasc Biol. 2010, 30:1263-1268.
27. Suen R.S., Rampersad S.N., Stewart D.J., Courtman D.W. Differential roles of endothelin-1 in angiotensin II-induced atherosclerosis and aortic aneurysms in apolipoprotein E-null mice. Am J Pathol. 2011, 179:1549-1559.
28. Saeed R.W., Varma S., Peng-Nemeroff T., Sherry B., Balakhaneh D., Huston J., et al. Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation. J Exp Med 2005, 201:1113-1123.
29. The F.O., Boeckxstaens G.E., Snoek S.A., Cash J.L., Bennink R., Larosa G.J., et al. Activation of the cholinergic anti-inflammatory pathway ameliorates postoperative ileus in mice. Gastroenterology 2007, 133:1219-1228.
30. Rosas-Ballina M., Ochani M., Parrish W.R., Ochani K., Harris Y.T., Huston J.M., et al. Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia. Proc Natl Acad Sci U S A 2008, 105:11008-11013.
31. Leib C., Goser S., Luthje D., Ottl R., Tretter T., Lasitschka F., et al. Role of the cholinergic antiinflammatory pathway in murine autoimmune myocarditis. Circ Res. 2011, 109:130-140.
32. Sandborn W.J. Nicotine therapy for ulcerative colitis: a review of rationale, mechanisms, pharmacology, and clinical results. Am J Gastroenterol 1999, 94:1161-1171.
33. van Maanen M.A., Lebre M.C., van der Poll T., LaRosa G.J., Elbaum D., Vervoordeldonk M.J., et al. Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice. Arthritis Rheum 2009, 60:114-122.
34. Inanaga K., Ichiki T., Miyazaki R., Takeda K., Hashimoto T., Matsuura H. Acetylcholinesterase inhibitors attenuate atherogenesis in apolipoprotein E-knockout mice. Atherosclerosis. 2010, 213:52-58.
35. Heeschen C., Jang J.J., Weis M., Pathak A., Kaji S., Hu R.S., et al. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 2001, 7:833-839.
36. Lau P.P., Li L., Merched A.J., Zhang A.L., Ko K.W., Chan L. Nicotine induces proinflammatory responses in macrophages and the aorta leading to acceleration of atherosclerosis in low-density lipoprotein receptor(-/-) mice. Arterioscler Thromb Vasc Biol 2006, 26:143-149.
37. Grady S.R., Drenan R.M., Breining S.R., Yohannes D., Wageman C.R., Fedorov N.B., et al. Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- and alpha 7-nicotine acetylcholine receptors. Neuropharmacology 2010, 58:1054-1066.
38. Papke R.L., Porter Papke J.K., Rose G.M. Activity of alpha7-selective agonists at nicotinic and serotonin 5HT3 receptors expressed in Xenopus oocytes. Bioorg Med Chem Lett 2004, 14:1849-1853.
39. Grottick A.J., Wyler R., Higgins G.A. The alpha4beta2 agonist SIB 1765F, but not the alpha7 agonist AR-R 17779, cross-sensitises to the psychostimulant effects of nicotine. Psychopharmacology (Berl) 2000, 150:233-236.
40. Yokotani K., Okada S., Nakamura K. Characterization of functional nicotinic acetylcholine receptors involved in catecholamine release from the isolated rat adrenal gland. Eur J Pharmacol 2002, 446:83-87.
41. Nonogaki K., Fuller G.M., Fuentes N.L., Moser A.H., Staprans I., Grunfeld C., et al. Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 1995, 136:2143-2149.
42. Murdoch C.E., Alom-Ruiz S.P., Wang M., Zhang M., Walker S., Yu B., et al. Role of endothelial Nox2 NADPH oxidase in angiotensin II-induced hypertension and vasomotor dysfunction. Basic Res Cardiol 2011, 106:527-538.
43. Guzik T.J., Harrison D.G. Endothelial NF-kappaB as a mediator of kidney damage: the missing link between systemic vascular and renal disease?. Circ Res 2007, 101:227-229.
44. Kranzhofer R., Schmidt J., Pfeiffer C.A., Hagl S., Libby P., Kubler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999, 19:1623-1629.
45. Guzik T.J., Hoch N.E., Brown K.A., McCann L.A., Rahman A., Dikalov S., et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007, 204:2449-2460.
46. Cassis L.A., Gupte M., Thayer S., Zhang X., Charnigo R., Howatt D.A., et al. ANG II infusion promotes abdominal aortic aneurysms independent of increased blood pressure in hypercholesterolemic mice. Am J Physiol Heart Circ Physiol 2009, 296:H1660-H1665.
47. Mullen G., Napier J., Balestra M., DeCory T., Hale G., Macor J., et al. (-)-Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the alpha 7 nicotinic acetylcholine receptor. J Med Chem 2000, 43:4045-4050.